PTX 4.65% 4.1¢ prescient therapeutics limited

Ann: PTX-100 Spotlight Presentation, page-18

  1. 2 Posts.
    lightbulb Created with Sketch. 1
    Hey all - long time reader of all things PTX here. I've got a question regarding the response rates/benefit rates presented at the latest briefing - hoping someone could shed some light on.

    The stats around the Overall Response Rates & Clinical Benefit Rates are composed of patients that have reached the end of cycle 4 of treatment (a cycle being 14 days). Most of the more recent patients unfortunately haven't reaching this time point. My question is around why the ORR/CBR is measured with the cohort of patients that have reached the end of C4? I'm assuming this has to do with the study design - but clarification would be helpful! Is this benchmark typical for a study like ours?

    From the swimmer plot, a number of patients would have gone through about 2 cycles of treatment. If the benchmark is arbitrary, and hypothetically we were to include these patients in calculating efficacy - does this mean PTX100 may not be as effective?

    https://hotcopper.com.au/data/attachments/5838/5838092-93e3dd74c7836d0034cd0ac0e285bff6.jpg

 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.1¢
Change
-0.002(4.65%)
Mkt cap ! $33.01M
Open High Low Value Volume
4.3¢ 4.5¢ 4.1¢ $30.55K 720.6K

Buyers (Bids)

No. Vol. Price($)
4 291817 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 940951 8
View Market Depth
Last trade - 16.10pm 30/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.